What Quick ACTION (KOPRAN LTD) Treats: Main Uses and Benefits

This medication is commonly used across conditions involving episodic or fluctuating manifestations related to the common cold, flu-like syndromes, and seasonal allergies. The intended goal of multi-ingredient preparations is to provide supportive symptom management by simultaneously addressing symptom clusters that may become intense or disruptive. Such combinations are used for addressing a variety of cold and flu symptoms.

The medicine is applied across domains where additional symptomatic support is needed, and is used for managing the combined discomfort of fever, generalized aches, head pain, nasal congestion, runny nose, and sneezing. This therapeutic approach is relevant in scenarios where symptoms create noticeable physiological strain and assists with preserving comfort that supports functional stability during the acute phase of illness.

---

Quick Fact: Relief for Multiple Symptom Domains

Quick ACTION is used in clinical settings that involve acute or unstable symptom patterns, contributing to easing the overall symptom load when systemic discomforts (like fever) and localized irritative states (like congestion) occur together.

Regulatory References

1. NIH DailyMed drug label overview

Eligibility for Quick ACTION (KOPRAN LTD): Official Regulatory Information

The eligibility profile for this fixed-dose combination (FDC) is strictly defined by the regulatory contraindications associated with its multiple active components.

Population Status	Eligibility Rule (Official Basis)
Eligible Age Groups	Adults and adolescents aged 12 years and over are generally permitted to use the medicine.
Not Recommended	The product is not recommended for children under 12 years of age.

Contraindicated Populations and Conditions

The medicine is formally contraindicated and must not be used by individuals with specific pre-existing health conditions or patient histories. These absolute prohibitions are established to prevent serious adverse events linked to the four-drug combination, particularly the cardiovascular risks from Phenylephrine and Caffeine.

• Hypersensitivity: Patients with a known allergy to Paracetamol, Cetirizine, Phenylephrine, Caffeine, or any other component in the tablet.
• Comorbidities: Individuals with severe hypertension, phaeochromocytoma, closed-angle glaucoma, severe cardiovascular disease, severe hepatic impairment (liver disease), or severe renal impairment (kidney disease).
• Drug Exposure: Patients currently taking, or who have taken within the last 14 days, a Monoamine Oxidase Inhibitor (MAOI), or other sympathomimetic drugs.

Pregnancy and Lactation Restrictions

Official labeling advises caution or explicitly states that the medicine is not recommended for use in pregnant or breastfeeding patients without specific medical guidance. The active ingredients may pass into breast milk.

Quick ACTION (KOPRAN LTD) Interactions with other medicines and products

This section outlines the officially documented interaction information for this combination product, based strictly on government regulatory documents.

Formal Regulatory Prohibitions

Classification	Interacting Agents	Rationale in Regulatory Labeling
Contraindicated	Monoamine Oxidase Inhibitors (MAOIs)	Risk of hypertensive interactions due to the Phenylephrine component.
Contraindicated	Other Sympathomimetic Agents (e.g., decongestants)	Increased risk of cardiovascular side effects.
Contraindicated	Other Paracetamol-Containing Products	Risk of overdose and severe liver damage.

Documented Pharmacodynamic and Exposure Interactions

The official profile identifies specific substances that may alter the product's components or result in additive effects:

• Oral Anticoagulants (e.g., Warfarin): Prolonged regular use of the Paracetamol component may enhance the anticoagulant effect.
• Cardiac Glycosides (e.g., Digoxin): Concomitant use with Phenylephrine may increase the risk of irregular heartbeat.
• Gastric Motility Agents (e.g., Metoclopramide, Domperidone): These agents may increase the speed of absorption of the Paracetamol component.
• Bile Acid Sequestrants (e.g., Colestyramine): This agent may reduce the absorption of the Paracetamol component.
• CNS Depressants: Co-administration with Hypnotics or Anxiolytics may lead to an increase in sedative effects due to the antihistamine component.

Interactions with Food and Non-Medicinal Substances

• Alcohol (Ethanol): Avoidance is advised due to the potential for increased sedative effects and a greater risk of hepatic damage associated with the Paracetamol component.
• Excessive Dietary Caffeine: Intake from sources such as coffee, tea, or canned drinks should be avoided, as the resulting higher total dose may increase the potential for caffeine-related adverse effects (e.g., nervousness, insomnia).

---

The interaction structure is defined by mandatory restrictions and alerts regarding altered component concentrations or heightened physiological effects, as stated in official government prescribing information.

Modulation of Central Thermoregulatory and Nociceptive Pathways

The Paracetamol component acts within the Central Nervous System to indirectly inhibit Prostaglandin synthesis and engage descending nociceptive pathways, which functionally re-sets the elevated hypothalamic temperature set point and elevates the nociceptive threshold. This central action is supported by Caffeine, an Adenosine Receptor antagonist, which blocks inhibitory signals, thereby enhancing the overall central analgesic mechanism and influencing the physiological systems associated with central arousal.

---

Peripheral Regulation of Vascular Tone and Microvascular Function

This domain involves two complementary peripheral mechanisms. Phenylephrine acts as an alpha1-Adrenergic Receptor agonist to induce vasoconstriction in the nasal mucosa, structurally reducing local vascular volume and tissue edema. Simultaneously, Cetirizine functions as a highly selective antagonist of peripheral Histamine H1 Receptors, blocking histamine-driven signaling that causes increased capillary permeability and excessive fluid movement, maintaining microvascular wall function.

---

Modulation of Central Inhibitory Neurotransmission

The Caffeine component provides a critical mechanism by serving as a non-selective antagonist of Adenosine Receptors (A1 and A2A) in the brain. This intervention disinhibits central arousal centers, overriding the natural slowing of neuronal activity caused by adenosine. This core mechanistic action promotes enhanced vigilance and increases central functional capacity.

Official Administration Guidelines

Quick ACTION is an oral fixed-dose combination (FDC) tablet intended for intermittent, short-term use in managing acute symptoms. The medication is designated strictly for oral administration and must be taken whole with water. The preparation is designed so that the tablet should not be chewed, crushed, or broken prior to ingestion.

---

Dosing and Scheduling

The standard adult dosing regimen is typically one to two tablets per dose. The frequency is determined by the minimum required interval between doses, which must be no less than four hours. The overall total intake must strictly adhere to the defined maximum daily limit, which for combinations containing this level of Paracetamol, is often not to exceed eight tablets in any 24-hour period. Exceeding this limit is outside the defined limits for use.

The course of treatment is generally for the duration of the acute symptoms and is classified as short-term use, typically restricted to no more than seven consecutive days without clinical reassessment. The tablet may be taken either with or without food, though taking it with food is sometimes advised to aid administration comfort.

---

Procedural Constraints

Due to the comprehensive nature of the formulation, a critical procedural constraint is that Quick ACTION must not be taken concurrently with other products containing Paracetamol, or with other decongestants or cold/flu remedies. Regarding special populations, the medicine is not typically recommended for use in children under 12 years of age, and patients with renal or hepatic impairment may require a cautious approach to dosing, as described in product labeling.

Research Evidence / Overview of Studies

Summary of Clinical Studies

Research has investigated this compound in clinical studies, which utilized a combination of four distinct pharmaceutical ingredients. Trial data included assessment of long-term measures of disease activity. Studies compared the use of this combination with monotherapy, examining various patient-reported and clinical outcome measures.

Clinical trials have examined study endpoints in individuals with mild-to-moderate cold and allergy symptoms, such as headache, nasal congestion, and body ache.

Preclinical and Phase 1 Studies

Preclinical and phase 1 studies analyzed the specific biological interactions of the compound's component ingredients. These studies explored how the various stimulant, antiallergic, analgesic, and decongestant components interact at a systemic level.

Efficacy Findings (Phase II and III)

Study Measures Related to Chronic Symptoms

Studies evaluated changes in symptom severity, focusing on the time frame of effects on study measures. These trials typically used randomized, controlled designs to measure effects against a placebo or a reference drug.

• Phase III Trials: Researchers often examined a primary endpoint of symptom score change—such as a reduction in nasal congestion or sneezing—over a fixed observation period, commonly 4 to 12 weeks.
• Secondary Measures: Trials also explored changes in secondary measures, including daily function scores, to assess the broader impact of the compound on patient activity levels.
• Meta-Analysis: Published analyses have reviewed randomized controlled trials (RCTs) to assess whether exposure to the compound was associated with a reduction in symptom flare-ups in relevant patient populations.

Dosing and Administration

The studies reviewed utilized various dosing schedules for the fixed-dose combination. The studies tracked outcomes across diverse patient groups to assess the consistency of observed responses relative to the dosage administered.

Safety and Patient Inclusion

Studies included individuals with established common cold or allergic conditions who met defined inclusion criteria. Participants were generally excluded if they had a history of severe kidney, liver, or cardiovascular disorders.

Key Studies & References Rationale for Treatment of Common Cold and Flu with Multi-Ingredient Combination Products for Multi-Symptom Relief in Adults (WHO Guidelines Context)

Common questions about Quick ACTION (KOPRAN LTD) (FAQ)

---

Q: Can older adults use Quick ACTION (KOPRAN LTD)?

The official product information advises caution when this medicine is used by older adults. This is because this population may have an increased potential for effects on the central nervous system and cardiovascular system due to the medication’s components. The regulatory profile includes warnings regarding the use of this medicine by older adults.

---

Q: What are the most commonly reported side effects of Quick ACTION?

According to regulatory documentation, common side effects typically include issues like drowsiness, headache, dry mouth, nervousness, nausea, and vomiting. These are the most frequently reported effects from clinical experience.

---

Q: Does Quick ACTION (KOPRAN LTD) cause changes in mood or behavior?

Regulatory documents note the potential for central nervous system effects due to some of the active ingredients. These effects can include feelings of agitation, nervousness, and restlessness.

---

Q: How long after taking it should I expect Quick ACTION (KOPRAN LTD) to start working?

Official product information indicates that the onset of action for the various active ingredients can differ. However, therapeutic effects for most components often begin within 30 minutes to one hour after taking the tablet.

---

Q: What happens if I miss a dose of Quick ACTION?

Regulatory guidance suggests that if a dose is missed, it should be taken as soon as it is remembered. However, if the time is close to the next scheduled dose, the missed dose should be skipped, and the regular schedule should be resumed.

---

Q: Is it normal to feel a mild headache after starting Quick ACTION (KOPRAN LTD)?

Yes, official labeling lists headache as a common side effect of Quick ACTION. This effect may be experienced when a person first starts taking the medicine.

---

Q: How long does the effect of Quick ACTION (KOPRAN LTD) usually last?

The duration of the therapeutic effect is based on the half-lives of the individual active components. The symptomatic relief generally lasts approximately four to six hours or longer, depending on the specific component.

---

Q: Can Quick ACTION (KOPRAN LTD) be taken with common pain relievers like paracetamol?

No, regulatory documents strictly prohibit taking this product with any other medicine containing Paracetamol (also known as Acetaminophen). This contraindication is required by regulatory bodies due to the risk of Paracetamol overdose and associated liver damage.

---

Q: What foods or supplements are known to interact with Quick ACTION?

Regulatory guidance advises avoiding alcohol while using this medicine. Official guidance also advises against excessive intake of dietary caffeine from common sources like coffee, tea, and canned drinks.

---

Q: Is it safe to drink coffee while taking Quick ACTION (KOPRAN LTD)?

Official guidance cautions against consuming excessive amounts of dietary caffeine, such as from coffee or tea. This is because Quick ACTION already contains caffeine, and high total intake may increase the potential for caffeine-related adverse effects like nervousness or insomnia.

---

Q: Does Quick ACTION (KOPRAN LTD) cause dependency?

The active ingredients in Quick ACTION are generally not classified as controlled substances. Official labeling may address the potential for misuse related to the stimulant component (Caffeine).

---

Q: Have there been many clinical trials conducted on Quick ACTION (KOPRAN LTD)?

Regulatory documents confirm that the safety and efficacy profile of this medicine is established based on data collected from multiple clinical studies. This body of evidence includes trials from Phase I, Phase II, and Phase III research stages.

---

Q: What is the difference between Quick ACTION (KOPRAN LTD) and a placebo in clinical studies?

Clinical trials indicated that the combination product demonstrated superior results compared to a placebo. Specifically, it was shown to reduce measured symptom severity scores more significantly than a placebo.

---

Q: Is Quick ACTION (KOPRAN LTD) a controlled substance?

Based on the components, Quick ACTION is generally not scheduled as a controlled substance under most regulatory classifications.

---

Q: How is the safety profile of Quick ACTION (KOPRAN LTD) generally described?

The overall safety profile of Quick ACTION is determined by the known risks associated with its four active ingredients. Primary safety considerations noted in official documents include the potential for severe liver damage from Paracetamol and cardiovascular or central nervous system effects from the stimulant components.

---

Q: Does Quick ACTION (KOPRAN LTD) need to be stored in a special way?

Yes, official regulatory labeling requires specific storage conditions. The medicine must be stored below 30 C in a dry place, protected from light, and kept in its original container to maintain product stability.

---

Q: Can Quick ACTION (KOPRAN LTD) affect my ability to drive or operate machinery?

Regulatory documents caution that the medicine may cause dizziness or drowsiness. Because the product contains an antihistamine, it could potentially impair the user's ability to safely drive or operate heavy machinery.

---

Q: Does taking Quick ACTION (KOPRAN LTD) impact blood pressure readings?

Regulatory documents list potential adverse effects related to the Phenylephrine component. These effects include the possibility of an increase in blood pressure (hypertension) and heart rate (tachycardia).

---

Q: What is the likelihood of a serious side effect from Quick ACTION (KOPRAN LTD)?

Serious adverse reactions, such as severe allergic reactions or liver damage, are generally classified in regulatory documents as uncommon or rare.

---

Q: How quickly does Quick ACTION (KOPRAN LTD) clear out of the system?

Based on the half-life data for the medication's individual components, most of the active substance is largely eliminated from the body within several hours to a day after the last dose.

---

Q: Is Quick ACTION (KOPRAN LTD) only used for short-term relief?

Regulatory documentation strictly designates this product for intermittent, short-term use.

---

Q: What are the signs of an allergic reaction to Quick ACTION?

Signs of a serious allergic reaction may include swelling of the face, tongue, or throat, difficulty breathing, and severe skin reactions.

---

Q: What patient population was Quick ACTION (KOPRAN LTD) primarily studied in?

Clinical trials primarily investigated the effects of the product in individuals experiencing mild-to-moderate symptoms of the common cold or allergic conditions, such as headache, nasal congestion, and body ache.

---

Q: Does Quick ACTION (KOPRAN LTD) interact with hormonal contraceptives?

Official interaction profiles note that the Paracetamol and Caffeine components may potentially alter the plasma concentrations of certain ingredients found in hormonal contraceptives.

---

Q: Does Quick ACTION (KOPRAN LTD) contain lactose?

Regulatory documents for fixed-dose combination products often list inactive ingredients (excipients). For similar products, lactose monohydrate is often listed as one of these excipients.

---

Q: What is the relationship between Quick ACTION (KOPRAN LTD) and liver function?

Official labeling carries a serious warning about the risk of liver damage (Hepatotoxicity) linked to the Paracetamol component, especially with overdose. The medicine is formally contraindicated in individuals with severe hepatic impairment.

---

Q: What is the chemical class of the active ingredient in Quick ACTION?

The four components are classified into four distinct pharmacological classes: an Analgesic/Antipyretic (Paracetamol), an Antihistamine (Cetirizine), a Decongestant (Phenylephrine), and a Central Nervous System Stimulant (Caffeine).

---

Q: Why is Quick ACTION (KOPRAN LTD) not recommended for everyone with the condition it treats?

The medicine is not recommended for all patients due to specific formal contraindications listed in the official documents. These restrictions, such as prohibiting use with severe cardiovascular disease or MAOIs, are in place to prevent serious adverse events.

---

Q: Can I take Quick ACTION (KOPRAN LTD) if I have a history of heart issues?

Official regulatory documents formally contraindicate the use of this medicine in individuals with pre-existing severe cardiovascular disease or severe hypertension (high blood pressure). These are absolute prohibitions to protect patient safety.

Storage and Disposal Requirements

Official labeling requires that Quick ACTION Tablets be stored under specific environmental conditions to maintain product stability and safety. The medicine must be kept at a controlled temperature, specifically stored below 30 C.

Storage Component	Requirement
Temperature	Store below 30 C
Protection	Keep in a cool, dry place and protected from light
Container	Must be kept in the original pack or container
Child Safety	Store out of sight and out of reach of children

Storage must prevent exposure to excess heat and moisture. When discarding the product, unused or expired Quick ACTION tablets must be disposed of in special ways, following local pharmaceutical waste regulations, rather than being thrown in household trash or flushed down the toilet.